CF
Vertex to acquire Crinetics in deal worth around $10bn
The deal includes an approved treatment for acromegaly and other pipeline candidates
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production
Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn
A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
Amended agreement sees Vertex take control of gene therapy programme
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients
Moderna inks R&D agreements with Vertex and Chiesi
Biotech agrees to separate deals for the development of gene-editing and mRNA therapies
Vertex’s triple combination CF therapy to become available on the NHS
The drug will immediately become available to thousands of cystic fibrosis patients
CRISPR gene-editing in cancer patients is safe, according to new study
Patients had no side effects following CRISPR treatment
Vertex continues upward trajectory with French Orkambi deal
Comes on the heels of similar reimbursement deal in England
Vertex reveals promising data from first CRISPR-treated patients
Investigational gene therapy has potentially curative effect
Vertex, NHS England and NICE finally reach agreement for Orkambi
Deal also includes Vertex’s other licensed cystic fibrosis medicines
Vertex scores FDA approval for CF triple therapy Trikafta
Decision comes only a few months after therapy was filed